Hashimoto's thyroiditis, which is also known as chronic lymphocytic thyroiditis (CLT), is currently the most prevalent autoimmune thyroid disease (ATD). Hashimoto's thyroiditis causes chronic inflammation of the thyroid tissues, and hypothyroidism in approximately 20-30% of patients, especially in the female population. However, the etiopathogenesis and treatment strategies of Hashimoto's thyroiditis are still incompletely defined. Creative Biolabs has been focusing on the drug development of autoimmune diseases for years and thus accumulated extensive experience from practice. We are capable of providing reliable cell-based therapy and antibody development services to global researchers.
The first report of Hashimoto's disease was made by Dr. Hashimoto in a German surgical journal when he was 30 years old. Today, Hashimoto's thyroiditis is more common in women than men (9:1) and occurs most commonly during the fifth decade of life. The thyroid in Hashimoto's disease has been described grossly as symmetrically enlarged and firm. Microscopically, the follicular epithelium ranges from hyperplastic to atrophic. The nuclei are enlarged and contain prominent nucleoli. There may also be considerable nuclear pleomorphism and hyperchromasia. Occasional intrafollicular multinucleated giant cells may be present. The clinical manifestations of Hashimoto's thyroiditis are often nonspecific, and many patients have no characteristic symptoms or signs. Some patients have a diffusely enlarged thyroid, and in some patients the symptoms of hypothyroidism progress insidiously.
There is no etiologic treatment for Hashimoto's thyroiditis. Hashimoto's thyroiditis is the most common cause of primary hypothyroidism, but only about 20% of patients become hypothyroid. Hypothyroid patients with a low serum free thyroxine (T4) level and an elevated serum TSH level require treatment with thyroid hormone. Hypothyroid patients require lifelong replacement therapy. The goal of replacement therapy is to restore and maintain the euthyroid state. Treatment of euthyroid patients is indicated to shrink large goiters. Surgery is occasionally indicated when malignancy is suspected and for goiters that cause compressive symptoms or cosmetic deformity. As an autoimmune disease of the thyroid gland, in this aspect similar to Graves' disease, which is now tested in antibody-based therapy, Hashimoto's thyroiditis therapeutic strategies may also consider antibody-based methods.
Fig.1 Therapeutic strategies for mitigating complications in Hashimoto’s thyroiditis and their undetermined efficacy.1
With extensive experience accumulated from hundreds of successful projects, Creative Biolabs is professional in the drug development of autoimmune diseases. Years of research have helped us accumulated not only experience, but also advanced technologies, mature technicians, and excellent experts specialized in drug development. With all these advantages, we are eager to support global researchers to promote the therapeutic strategies development for Hashimoto's thyroiditis through our high-quality services. Our services include but not limited to:
As a global-leading CRO company, Creative Biolabs has an advanced and comprehensive drug development platform to provide customer-satisfied services to global clients. If you are interested in antibody development or cell therapy, please feel free to contact us for more information.
Reference
For Research Use Only | Not For Clinical Use
Contact us
USA
Creative Biolabs is a world-leading CRO that is skilled in developing novel therapies,
especially in antibody and cell therapy for autoimmune diseases.
Copyright © 2024 Creative Biolabs. All Rights Reserved.
